Henlius Biotech Expands Partnership with Palleon Pharmaceuticals for Autoimmune Disease Treatment
Shanghai Henlius Biotech Inc. (HKG: 2696), a leading biotechnology company based in China, has announced...
Auto-immune
Everest Medicines’ Velsipity NDA for Ulcerative Colitis Accepted by China’s NMPA
China-based Everest Medicines (HKG: 1952) has announced that the National Medical Products Administration (NMPA) has...
Johnson & Johnson Submits sBLA to FDA for Simponi in Pediatric Ulcerative Colitis
US pharmaceutical major Johnson & Johnson (J&J, NYSE: JNJ) has announced the submission of a...
Accropeutics Gets FDA Green Light for Phase II UC Study of RIPK2 Inhibitor AC-101
Accropeutics Inc., a clinical-stage biotechnology company with operations in New York, US, and Suzhou, China,...
EMA’s CHMP Supports Approval of Eli Lilly’s Omvoh (Mirikizumab) for Crohn’s Disease
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recently...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Lupus Nephritis Clinical Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has obtained approval from...
Abbisko Therapeutics Presents Positive Phase II Results for Pimicotinib in cGvHD at ASH
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the presentation of preliminary Phase II...
InventisBio’s Oral TYK2 Inhibitor D-2570 Achieves Positive Results in Phase II Psoriasis Study
China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) has announced the successful completion of a Phase...
UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China
Belgium based UCB (EBR: UCB) is fulfilling its commitment to enhance attention to innovative products...
ImmuneOnco Biopharmaceuticals Receives NMPA Approval for Lupus Nephritis Phase II Study
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced receiving approval from...
Thederma’s TAP-1503 Cream Approved by China’s NMPA for Atopic Dermatitis Treatment
China-based Thederma has announced that its TAP-1503 cream has been granted approval by the National...
E-nitiate Biopharmaceuticals Strikes Licensing Deal with Joincare for QY101 Inhaler Rights
China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a joint venture between VivaVision Biotech and Betta Pharmaceuticals...
J&J Submits sBLA to FDA for Subcutaneous Tremfya Regimen in Ulcerative Colitis
Johnson & Johnson (J&J; NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to...
UCB’s Bimzelx Receives US FDA Approval for Moderate to Severe Hidradenitis Suppurativa
Belgium-based biopharmaceutical company UCB (FRA: UNC) has announced that the US Food and Drug Administration...
UCB and Biogen’s Dapirolizumab Pegol Shows Promise in Phase III SLE Study
Partners UCB (FRA: UNC) and Biogen Inc. (NASDAQ: BIIB) have announced positive results from a...
Everest Medicines’ Nefecon Receives Full Approval from South Korea’s MFDS for IgAN Treatment
China-based Everest Medicines (HKG: 1952) has announced that it has received full approval from the...
Sunshine Guojian Pharmaceutical’s SSGJ-608 Files for NMPA Approval in Plaque Psoriasis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG: 1530),...
Sanofi’s Dupixent sBLA for Chronic Spontaneous Urticaria Accepted by FDA for Review
French pharmaceutical giant Sanofi has announced that the US Food and Drug Administration (FDA) has...
Jiangsu Kanion Pharmaceutical Gets FDA Approval to Test KYS202004A for Psoriasis
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a Chinese pharmaceutical company, has announced that it...
Huadong Medicine Co., Ltd Receives NMPA Approval for Stelara Biosimilar SaiLeXin
Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has...